[PDF] Top 20 Cálculo de las reservas de un yacimiento (Cálculo)
Has 6796 "Cálculo de las reservas de un yacimiento (Cálculo)" found on our website. Below are the top 20 most common "Cálculo de las reservas de un yacimiento (Cálculo)".
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
... overall response by irRECIST1.1 (irBOR) during ther- apy was assigned to each patient, using the thresholds of ≥30% decrease compared to baseline for partial response (PR) and ≥20% increase compared ... See full document
5
<p>Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD</p>
... as non-invasive methods for assessing lung in fl ammation and pulmonary function, spirometry and fraction of exhaled nitric oxide (FeNO) are widely ...of patients with asthma and/or COPD comprise ... See full document
10
<p>Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions</p>
... an inhibitor of the vascular endothelial growth factor receptor (VEGFR) 2 and 3, epidermal growth factor receptor (EGFR) and ...treated advanced NSCLC in combination with docetaxel (ZODIAC) 38 or pemetrexed ... See full document
20
Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations
... first-line therapy or is equally effective when administered as a second-line therapy ...TKI therapy for EGFR mutated NSCLC in previous clinical trials differed ...mutated patients in the ... See full document
260
<p>Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer</p>
... of immune checkpoint inhibitors have been reported to be linked with immune-related adverse events ...In patients with advanced non-small-cell lung ... See full document
16
PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
... Abstract: Lung cancer is the leading cause of cancer death in males and the second leading cause of death in females ...worldwide. Non-small-cell lung cancer ... See full document
5
Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials
... of response was significantly longer for patients receiving immunotherapy (HR: ...overall response rate was also higher for patients who received any anti-PD-1/anti-PD-L1 ... See full document
76
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
... with advanced NSCLC (stage IIIB and IV), eligible for treatment with checkpoint inhibitors towards PD-L1 or PD − 1 receptors were asked to participate in this prospective exploratory cohort ... See full document
12
New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response
... conventional-targeted therapy studies in less restricted patient populations that incorporate retrospective analyses of well-defined biomarkers ...are: 1) the control of type I error rate; 2) the ... See full document
16
Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma
... of response of EWS to immune checkpoint blockade with ...of PD- 1-directed therapy in recurrent and metastatic EWS is warranted and await the results of the SARC028 phase II study ... See full document
19
Salvage treatment with apatinib for advanced non-small-cell lung cancer
... the Response Evaluation Criteria in Solid Tumors (RECIST ...complete response (CR), partial response (PR), stable disease (SD), and progressive disease ...objective response and stabilization ... See full document
7
Radiation-induced esophagitis in lung cancer
... Abstract: Radiation-induced esophagitis is the most common local acute toxicity of radio- therapy (RT) delivered for the curative or palliative intent treatment of lung cancer. Although concurrent ... See full document
8
Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer.
... tumours (including NSCLC) following treatment conferred a marked improvement in progression-free and overall survival, even in the presence of residual soft tissue on CT [10, 28-31] (figure 3). Limitations remain due to ... See full document
172
SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer
... inflammatory response was visually observed from the SPECT images acquired after the 2 weeks of bevaci- zumab ...high cell density and vascularity, likely responsible for the increased ...SPECT 1 and ... See full document
23
<em>EGFR</em> mutations as a prognostic and predictive marker in non-small-cell lung cancer
... NSCLC patients treated with cytotoxic ...NSCLC patients with EGFR mutations achieved better therapeutic effect and longer survival time, one possible rea- son is that EGFR mutation patients have a ... See full document
5
Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report
... shown to activate immune responses. Abscopal effects were used to describe the phenomenon of tumor regression in untreated metastatic lesions after local treatment, such as radiotherapy [18]. The potential ... See full document
7
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
... radiation therapy. During follow- up, a surveillance PET scan approximately 11 months later was notable for new metastatic liver, mediastinal, para-aortic and right lower lobe ...having PD-L1 ... See full document
8
Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer
... multikinase inhibitor, is an approved third-line or later therapy for advanced NSCLC according to the Chinese Food and Drug Administration (CFDA), based on the ALTER 0303 study ...Combination ... See full document
75
Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature
... of immune check- point inhibitors [12, ...eight patients reported by Heinzerling et ...effusion during PD-1 inhibitor treatment for advanced NSCLC is rare, and only has ... See full document
35
Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review
... in patients pro- gressing on the second-generation ALK-tyrosine kinase inhibitor (TKI) ...in patients pretreated with more than two courses of ALK-TKIs [2, ...ALK inhibitor therapy also ... See full document
91
Related subjects